Alphaform AG / Key word(s): Final Results 09.03.2012 11:25 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- AD HOC PUBLICATION pursuant to § 15 of the German Securities Trading Act Alphaform vastly improves revenues and EBITDA, according to provisional figures - Return still clearly negative due to book value depreciation at Medimet Feldkirchen, 9 March 2012 - Alphaform AG - a specialist in additive manufacturing and one of the leading companies in the area of orthopaedic implants and instruments - experienced strong growth in the financial year 2011. According to provisional figures, consolidated revenues increased by 28% to EUR 26.4 million. In the financial year 2010, they had totalled EUR 20.7 million. In the process, revenues grew markedly both in the Prototyping & Additive Manufacturing business area and in Medical Technology. EBITDA rose to EUR 1.0 million, following EUR 0.8 million in the previous year. This is an increase of 25%. Net profit remained negative at EUR -1.5 million (previous year EUR -1.4 million). This is partly due to extraordinary book value depreciation of EUR 1.0 million at the subsidiary Medimet GmbH. Irrespective of this, the strategic repositioning introduced in the spring of 2008 by expanding the business into the area of Medical Technology has proved correct. This business area now generates approximately 40% of consolidated revenues. However, in 2011, earnings in the Medical Technology division suffered under high pricing pressure and, due to a strong growth, under a disproportionateupturn in costs. Thus, in this division, the operating business margin remained below expectations. Therefore, in the second half of 2011 in particular, Alphaform concentrated on reducing costs in the Medical Technology division. The management expects that the measures that have been introduced and already implemented will have a positive impact on earnings in 2012. In the traditional area of prototype making with additive manufacturing techniques (prototyping), Alphaform benefited considerably from a general upturn. Revenuesthat had been lost as a result of the economic crisis and a heavy decline of the Formula-1-Business had now vastly grown again. In 2011, incoming orders for prototyping received by Alphaform - adjusted for Formula 1 - again reached the 2008 level. Operating earnings also developed in a very pleasing manner in this division as a result of the cost reduction measures performed during the crisis. Forecast In the financial year 2012, Alphaform will concentrate on further improving Group earnings. In the process, the particular objective is to raise the results of operations of the Medical Technology division to the customary level in this segment which, in 2011, were unsatisfactory and weighed down the Group as a whole. The Group has strengthened capacities in additive manufacturing in the past few months in order to meet the logistical requirements and do justice to the rise in output, the Group has strengthened capacities in additive manufacturing. Alphaform anticipates that the measures that have been introduced and already carried out in Medical Technology will have a positive impact as well as the development in the Prototyping & Additive Manufacturing division will remain positive. Thus, Alphaform is expecting net income on Group level in 2012. Contact: Dr. Gordon Guth CFO ALPHAFORM AG KapellenstraÃe 10 85622 Feldkirchen Tel.: +49 89 905002 83 Fax: +49 89 9050021083 mailto:gguth@alphaform.de Internet: www.alphaform.de --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About Alphaform Alphaform AG, headquartered in Feldkirchen near Munich, is a contract manufacturer for complex components and products produced in smaller batches, founded in 1996. The company is one of the Eruoprean market leaders in rapid manufacturing and rapid prototyping. The company has a leading position throughout Europe in the manufacture of orthopaedic implants and instruments. The core competence of Alphaform lies in the provision of comprehensive application expertise with regard to processes and materials for the rapid production of complex prototypes, tools, single components and small series of plastics and metals. The focus of the company's work lies in orthopaedic and medical technology as well as automotive. About rapid manufacturing Rapid manufacturing is automatic shift manufacturing of plastic and metal parts, directly from CAD files and without casting moulds or press moulds. Also known as direct manufacturing, 3D printing or e-manufacturing, rapid manufacturing is seen globally as a growth field. Fore some years, these manufacturing methods have enabled rapid tooling and rapid prototyping. 09.03.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Alphaform AG KapellenstraÃe 10 85622 Feldkirchen Germany Phone: +49 (0)89 905002 - 0 Fax: +49 (0)89 905002 - 90 E-mail: ir@alphaform.de Internet: www.alphaform.de ISIN: DE0005487953 WKN: 548795 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Alphaform AG: Alphaform vastly improves revenues and EBITDA, according to provisional figures - Return still clearly negative due to book value depreciation ad Medimet
| Source: EQS Group AG